11:17:29 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-28 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-05-30 Kvartalsrapport 2024-Q1
2024-03-21 Ordinarie utdelning FLUO 0.00 DKK
2024-03-20 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-29 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-03-22 Ordinarie utdelning FLUO 0.00 DKK
2023-03-21 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-31 Kvartalsrapport 2022-Q1
2022-05-19 Ordinarie utdelning FLUO 0.00 DKK
2022-05-18 Årsstämma 2022
2022-03-30 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-05-03 Ordinarie utdelning FLUO 0.00 DKK
2021-02-26 Bokslutskommuniké 2020
2021-02-09 Årsstämma 2021
2020-11-20 Kvartalsrapport 2020-Q3
2020-08-14 Kvartalsrapport 2020-Q2
2020-05-27 Kvartalsrapport 2020-Q1
2020-04-09 Ordinarie utdelning FLUO 0.00 DKK
2020-04-08 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-29 Kvartalsrapport 2019-Q3
2019-05-31 Kvartalsrapport 2019-Q1

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
FluoGuide är ett danskt bolag verksamma inom medicinteknik. Bolaget affärsfokus återfinns inom forskning och utveckling av behandlingar mot olika cancerformer, med störst fokus på utveckling av produkter som vägleder vid kirurgiska ingrepp. Produkterna binder till sig cancercellerna som då lyser upp och är avsedda att användas för att med precision kunna ta bort skadliga tumörer i patientens vävnad.
2021-12-22 11:57:25
Copenhagen, Denmark, 22 December 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has submitted a CTA to initiate the phase II trial in lung cancer. The clinical trial will be conducted at Rigshospitalet in Denmark.

Following approval from the Danish Medicines Agency, FluoGuide will initiate the phase II trial in lung cancer in collaboration with Department of Cardiothoracic Surgery at the University Hospital, Rigshospitalet, in Denmark.

The phase II trial is designed to enrol up to 24 patients with non small cell lung cancer (NSCLC). The primary endpoint is sensitivity defined as the relative number of patients, where FG001 lights up the cancer. FluoGuide expects the patients to be enrolled during 2022 and top line results to be available late 2022. The trial includes 2 interim evaluations after 8 and 16 patients, respectively.

FluoGuide has selected lung cancer as the second indication to investigate after malignant glioma. The selection of lung cancer is due to a high unmet need, evidence uPAR being overexpressed in the lung cancer and that the surgeons are familiar with using optical endoscopes during surgery.

“Lung cancer is the second most frequent form of cancer worldwide and the deadliest. Early detection and lung sparring minimal invasive surgery is key for survival and quality of life” says principal investigator and professor René Horsleben Petersen, MD PhD and continues: “This requires precise surgery, and I have a great expectation of studying the effect of FG001 in guiding future lung cancer surgery.”

Due of the flare up of the ongoing COVID-19 pandemic, it may result in delay of regulatory approval and thus the patient inclusion.